This trial will test if a software that monitors treatment-related side effects and creates self-care management plans for these symptoms is feasible to implement among patients with metastatic renal cell carcinoma. Additionally, it will collect preliminary data on treatment-related side effects, quality of life, distress level, and drug adherence.
4 Primary · 5 Secondary · Reporting Duration: 48 weeks
50 Total Participants · 1 Treatment Group
Primary Treatment: Carevive software · No Placebo Group · N/A
Age 18+ · All Participants · 6 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: